- Home
- SNSE vs IMNN Comparison
SNSE vs IMNN Comparison
Compare SNSE & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- IMNN
- Stock Information
- Founded
- SNSE 2005
- IMNN 1982
- Country
- SNSE United States
- IMNN United States
- Employees
- SNSE N/A
- IMNN N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- IMNN Health Care
- Exchange
- SNSE Nasdaq
- IMNN Nasdaq
- Market Cap
- SNSE 10.8M
- IMNN 12.1M
- IPO Year
- SNSE 2021
- IMNN 1985
- Fundamental
- Price
- SNSE $8.17
- IMNN $0.60
- Analyst Decision
- SNSE Strong Buy
- IMNN Buy
- Analyst Count
- SNSE 3
- IMNN 2
- Target Price
- SNSE $86.67
- IMNN $14.00
- AVG Volume (30 Days)
- SNSE 12.9K
- IMNN 1.3M
- Earning Date
- SNSE 08-05-2025
- IMNN 08-13-2025
- Dividend Yield
- SNSE N/A
- IMNN N/A
- EPS Growth
- SNSE N/A
- IMNN N/A
- EPS
- SNSE N/A
- IMNN N/A
- Revenue
- SNSE N/A
- IMNN N/A
- Revenue This Year
- SNSE N/A
- IMNN N/A
- Revenue Next Year
- SNSE N/A
- IMNN N/A
- P/E Ratio
- SNSE N/A
- IMNN N/A
- Revenue Growth
- SNSE N/A
- IMNN N/A
- 52 Week Low
- SNSE $5.00
- IMNN $0.37
- 52 Week High
- SNSE $17.40
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- SNSE 50.67
- IMNN 35.40
- Support Level
- SNSE $8.76
- IMNN $0.70
- Resistance Level
- SNSE $9.27
- IMNN $0.86
- Average True Range (ATR)
- SNSE 0.52
- IMNN 0.07
- MACD
- SNSE -0.00
- IMNN -0.03
- Stochastic Oscillator
- SNSE 42.84
- IMNN 0.05
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).